Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort

Mitzi M. Gonzales; Chen Pin Wang; Meghan I. Short; Danielle M. Parent; Tiffany Kautz; Daniel MacCarthy; Claudia L. Satizabal; David Andrés González; Donald R. Royall; Habil Zare; Sid O'Bryant; Gladys E. Maestre; Russell P. Tracy; Sudha Seshadri

doi:10.1002/dad2.12298

Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort

Mitzi M. Gonzales, Chen Pin Wang, Meghan I. Short, Danielle M. Parent, Tiffany Kautz, Daniel MacCarthy, Claudia L. Satizabal, David Andrés González, Donald R. Royall, Habil Zare, Sid O'Bryant, Gladys E. Maestre, Russell P. Tracy, Sudha Seshadri

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Introduction: The clinical translation of biofluid markers for dementia requires validation in diverse cohorts. The study goal was to evaluate if blood biomarkers reflecting diverse pathophysiological processes predict disease progression in Mexican American adults. Methods: Mexican American adults (n = 745), 50 years of age and older, completed annual assessments over a mean of 4 years. Serum collected at baseline was assayed for total tau, neurofilament light (NFL), ubiquitin carboxyl-terminal hydrolase LI, glial fibrillary acidic protein (GFAP), soluble cluster of differentiation 14 (sCD14), and chitinase-3-like protein 1 (YKL-40). Results: Higher GFAP and NFL were associated with global cognitive decline. Only GFAP was associated with increased incident dementia risk (hazard ratio: 1.611 (95% confidence interval: 1.204-2.155)) and inclusion of additional biomarkers did not improve model fit. Discussion: Among a panel of six blood biomarkers previously associated with neurodegenerative disease, only GFAP predicted incident dementia in our cohort. The findings suggest that blood GFAP levels may aid dementia-risk prediction among Mexican American adults.

Original language	English (US)
Article number	e12298
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	14
Issue number	1
DOIs	https://doi.org/10.1002/dad2.12298
State	Published - 2022

Keywords

Alzheimer's disease
GFAP
Hispanic
Latinos
Mexican American
NFL
UCHL-1
YKL-40
biomarkers
soluble CD14
total tau

ASJC Scopus subject areas

Clinical Neurology
Psychiatry and Mental health

Access to Document

10.1002/dad2.12298

Cite this

Gonzales, M. M., Wang, C. P., Short, M. I., Parent, D. M., Kautz, T., MacCarthy, D., Satizabal, C. L., González, D. A., Royall, D. R., Zare, H., O'Bryant, S., Maestre, G. E., Tracy, R. P., & Seshadri, S. (2022). Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 14(1), Article e12298. https://doi.org/10.1002/dad2.12298

Gonzales, MM, Wang, CP, Short, MI, Parent, DM, Kautz, T, MacCarthy, D, Satizabal, CL, González, DA, Royall, DR , Zare, H, O'Bryant, S, Maestre, GE, Tracy, RP & Seshadri, S 2022, 'Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort', Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, vol. 14, no. 1, e12298. https://doi.org/10.1002/dad2.12298

@article{713820d91df842739daf8d58049550a2,

title = "Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort",

abstract = "Introduction: The clinical translation of biofluid markers for dementia requires validation in diverse cohorts. The study goal was to evaluate if blood biomarkers reflecting diverse pathophysiological processes predict disease progression in Mexican American adults. Methods: Mexican American adults (n = 745), 50 years of age and older, completed annual assessments over a mean of 4 years. Serum collected at baseline was assayed for total tau, neurofilament light (NFL), ubiquitin carboxyl-terminal hydrolase LI, glial fibrillary acidic protein (GFAP), soluble cluster of differentiation 14 (sCD14), and chitinase-3-like protein 1 (YKL-40). Results: Higher GFAP and NFL were associated with global cognitive decline. Only GFAP was associated with increased incident dementia risk (hazard ratio: 1.611 (95% confidence interval: 1.204-2.155)) and inclusion of additional biomarkers did not improve model fit. Discussion: Among a panel of six blood biomarkers previously associated with neurodegenerative disease, only GFAP predicted incident dementia in our cohort. The findings suggest that blood GFAP levels may aid dementia-risk prediction among Mexican American adults.",

keywords = "Alzheimer's disease, GFAP, Hispanic, Latinos, Mexican American, NFL, UCHL-1, YKL-40, biomarkers, soluble CD14, total tau",

author = "Gonzales, {Mitzi M.} and Wang, {Chen Pin} and Short, {Meghan I.} and Parent, {Danielle M.} and Tiffany Kautz and Daniel MacCarthy and Satizabal, {Claudia L.} and Gonz{\'a}lez, {David Andr{\'e}s} and Royall, {Donald R.} and Habil Zare and Sid O'Bryant and Maestre, {Gladys E.} and Tracy, {Russell P.} and Sudha Seshadri",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.",

year = "2022",

doi = "10.1002/dad2.12298",

language = "English (US)",

volume = "14",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort

AU - Gonzales, Mitzi M.

AU - Wang, Chen Pin

AU - Short, Meghan I.

AU - Parent, Danielle M.

AU - Kautz, Tiffany

AU - MacCarthy, Daniel

AU - Satizabal, Claudia L.

AU - González, David Andrés

AU - Royall, Donald R.

AU - Zare, Habil

AU - O'Bryant, Sid

AU - Maestre, Gladys E.

AU - Tracy, Russell P.

AU - Seshadri, Sudha

PY - 2022

Y1 - 2022

N2 - Introduction: The clinical translation of biofluid markers for dementia requires validation in diverse cohorts. The study goal was to evaluate if blood biomarkers reflecting diverse pathophysiological processes predict disease progression in Mexican American adults. Methods: Mexican American adults (n = 745), 50 years of age and older, completed annual assessments over a mean of 4 years. Serum collected at baseline was assayed for total tau, neurofilament light (NFL), ubiquitin carboxyl-terminal hydrolase LI, glial fibrillary acidic protein (GFAP), soluble cluster of differentiation 14 (sCD14), and chitinase-3-like protein 1 (YKL-40). Results: Higher GFAP and NFL were associated with global cognitive decline. Only GFAP was associated with increased incident dementia risk (hazard ratio: 1.611 (95% confidence interval: 1.204-2.155)) and inclusion of additional biomarkers did not improve model fit. Discussion: Among a panel of six blood biomarkers previously associated with neurodegenerative disease, only GFAP predicted incident dementia in our cohort. The findings suggest that blood GFAP levels may aid dementia-risk prediction among Mexican American adults.

AB - Introduction: The clinical translation of biofluid markers for dementia requires validation in diverse cohorts. The study goal was to evaluate if blood biomarkers reflecting diverse pathophysiological processes predict disease progression in Mexican American adults. Methods: Mexican American adults (n = 745), 50 years of age and older, completed annual assessments over a mean of 4 years. Serum collected at baseline was assayed for total tau, neurofilament light (NFL), ubiquitin carboxyl-terminal hydrolase LI, glial fibrillary acidic protein (GFAP), soluble cluster of differentiation 14 (sCD14), and chitinase-3-like protein 1 (YKL-40). Results: Higher GFAP and NFL were associated with global cognitive decline. Only GFAP was associated with increased incident dementia risk (hazard ratio: 1.611 (95% confidence interval: 1.204-2.155)) and inclusion of additional biomarkers did not improve model fit. Discussion: Among a panel of six blood biomarkers previously associated with neurodegenerative disease, only GFAP predicted incident dementia in our cohort. The findings suggest that blood GFAP levels may aid dementia-risk prediction among Mexican American adults.

KW - Alzheimer's disease

KW - GFAP

KW - Hispanic

KW - Latinos

KW - Mexican American

KW - NFL

KW - UCHL-1

KW - YKL-40

KW - biomarkers

KW - soluble CD14

KW - total tau

UR - http://www.scopus.com/inward/record.url?scp=85136268329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136268329&partnerID=8YFLogxK

U2 - 10.1002/dad2.12298

DO - 10.1002/dad2.12298

M3 - Article

C2 - 35356487

AN - SCOPUS:85136268329

SN - 2352-8729

VL - 14

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

IS - 1

M1 - e12298

ER -

Blood biomarkers for cognitive decline and clinical progression in a Mexican American cohort

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this